Table 4.
N (%) | OR (95% CI) | |
---|---|---|
Age group (years) | ||
19–44 | 367 (24.7) | Reference |
45–54 | 298 (20.1) | 1.07 (0.74–1.55) |
55–64 | 307 (20.7) | 0.99 (0.68–1.44) |
65–74 | 263 (17.7) | 1.01 (0.67–1.52) |
75 or older | 367 (24.7) | 0.81 (0.51–1.28) |
Sex | ||
Female | 691 (46.6) | Reference |
Male | 792 (53.4) | 1.45 (1.12–1.88) |
Race | ||
White | 362 (24.4) | 0.86 (0.61–1.19) |
African American | 554 (37.4) | Reference |
Other | 432 (29.1) | 1.21 (0.90–1.63) |
Comorbidities | ||
COPD | 84 (5.7) | 1.50 (0.87–2.58) |
Hypertension | 897 (60.5) | 1.23 (0.91–1.67) |
Hyperlipidemia | 592 (39.9) | 1.17 (0.87–1.56) |
Diabetes mellitus | 634 (42.8) | 1.21 (0.93–1.58) |
Prior CVA | 121 (8.2) | 1.43 (0.91–2.25) |
Congestive heart failure | 218 (14.7) | 1.45 (1.00–2.12) |
Chronic kidney disease | 306 (20.6) | 0.89 (0.60–1.32) |
Current ESRD | 106 (7.1) | 1.14 (0.67–1.97) |
Obstructive sleep apnea | 154 (10.4) | 1.58 (1.07–2.33) |
Blood‐borne cancer | 18 (1.2) | 3.53 (1.26–9.86) |
Symptoms | ||
Anosmia | 104 (9.4) | 1.06 (0.63–1.78) |
Cough | 800 (71.9) | 0.95 (0.70–1.30) |
Headache | 43 (3.9) | 0.69 (0.29–1.65) |
Myalgias | 246 (22.1) | 0.89 (0.62–1.28) |
Labs | ||
WBC | ||
≥10 | 339 (24.1) | 1.58 (1.15–2.17) |
≤ 4 | 144 (10.2) | 1.00 (0.65–1.54) |
ALC ≤ 1.5 | 1,108 (79.1) | 1.00 (0.71–1.40) |
ANC/ALC ≥ 6 | 569 (40.6) | 1.61 (1.20–2.17) |
Total bilirubin > 1.3 | 82 (6.2) | 1.02 (0.61–1.71) |
Albumin < 3.5 | 780 (58.8) | 1.80 (1.39–2.32) |
AST > 40 | 657 (49.5) | 1.66 (1.20–2.29) |
ALT > 40 | 466 (35.3) | 0.88 (0.63–1.22) |
LDH ≥ 245 | 605 (86.4) | 1.14 (0.66–1.97) |
Lactate ≥ 2 | 259 (29.7) | 1.95 (1.40–2.73) |
D‐dimer > 0.49 | 323 (79.4) | 1.44 (1.05–1.97) |
C‐reactive protein >8 | 633 (98.3) | 1.41 (0.95–2.11) |
Ferritin > 300 (men) or 150 (women) | 563 (81.1) | 1.14 (0.69–1.87) |
Troponin > 0.9 | 87 (22.3) | 3.65 (2.03–6.57) |
BMI = body mass index; CVA = cerebrovascular accident; ESRD = end‐stage renal disease (on dialysis); HIV = human immunodeficiency virus.